Literature DB >> 16479372

Effects of anti-phencyclidine and anti-(+)-methamphetamine monoclonal antibodies alone and in combination on the discrimination of phencyclidine and (+)-methamphetamine by pigeons.

J R Daniels1, W D Wessinger, W C Hardwick, M Li, M G Gunnell, C J Hall, S M Owens, D E McMillan.   

Abstract

RATIONALE: Drug-specific monoclonal antibodies against phencyclidine (PCP) and (+)-methamphetamine [(+)-METH] should bind to these drugs to block their discriminative stimulus effects.
OBJECTIVES: To determine if mouse monoclonal antibodies against PCP and (+)-METH can block the discriminative stimulus effects of the drugs in pigeons.
MATERIALS AND METHODS: Pigeons were trained to discriminate among intramuscular injections of saline, 1 mg/kg PCP, and 2 mg/kg (+)-METH. After responding stabilized, cumulative dose-response curves were obtained for PCP and (+)-METH. Doses of an anti-PCP antibody at 620 mg/kg (anti-PCP mAb6B5) with a K (D) of 1.3 nM for PCP and no measurable affinity for (+)-METH and 1,000 mg/kg doses of anti-(+)-METH antibody (anti-METH mAb6H7) with a K (D) of 41 nM for (+)-METH and no measurable affinity for PCP were subsequently administered, first alone and later in combination after which the dose-response curves were redetermined.
RESULTS: When the antibodies were given alone, the anti-PCP antibody blocked the discriminative stimulus effects of PCP, but not those of (+)-METH, and the anti-(+)-METH antibody blocked the discriminative stimulus effects of (+)-METH, but not those of PCP. The anti-PCP antibody shifted the PCP dose-response curve further to the right and for a longer time than the anti-(+)-METH antibody shifted the dose response curve for (+)-METH. When the anti-PCP and anti-(+)-METH antibodies were administered on the same day, the discriminative stimulus effects of both drugs were completely blocked 1 day after antibody administration.
CONCLUSIONS: These experiments demonstrate the high specificity of the antibodies for the drugs to which they bind and show that monoclonal antibodies can be combined to antagonize the effects of more than one drug.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16479372     DOI: 10.1007/s00213-005-0299-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  20 in total

Review 1.  Intravenous immune globulin in the management of severe Rh D hemolytic disease.

Authors:  T F Porter; R M Silver; G M Jackson; D W Branch; J R Scott
Journal:  Obstet Gynecol Surv       Date:  1997-03       Impact factor: 2.347

2.  Anti-phencyclidine monoclonal antibodies provide long-term reductions in brain phencyclidine concentrations during chronic phencyclidine administration in rats.

Authors:  J W Proksch; W B Gentry; S M Owens
Journal:  J Pharmacol Exp Ther       Date:  2000-03       Impact factor: 4.030

3.  Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats.

Authors:  J L Valentine; S M Owens
Journal:  J Pharmacol Exp Ther       Date:  1996-08       Impact factor: 4.030

4.  Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats.

Authors:  K A Byrnes-Blake; F I Carroll; P Abraham; S M Owens
Journal:  Int Immunopharmacol       Date:  2001-02       Impact factor: 4.932

5.  Structure-activity relationships of arylcyclohexylamines as discriminative stimuli in pigeons.

Authors:  D E McMillan; E B Evans; W D Wessinger; S M Owens
Journal:  J Pharmacol Exp Ther       Date:  1988-12       Impact factor: 4.030

6.  Amphetamine-like effects of anorectics and related compounds in pigeons.

Authors:  S M Evans; C E Johanson
Journal:  J Pharmacol Exp Ther       Date:  1987-06       Impact factor: 4.030

7.  Generalization of the discriminative stimulus properties of phencyclidine to other drugs in the pigeon using color tracking under second order schedules.

Authors:  D E McMillan
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

8.  Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat.

Authors:  D E McMillan; W C Hardwick; M Li; M G Gunnell; F I Carroll; P Abraham; S M Owens
Journal:  J Pharmacol Exp Ther       Date:  2004-03-01       Impact factor: 4.030

9.  Very high dose intravenous gammaglobulin in thrombocytopenia of pregnancy.

Authors:  J Gibson; P P Laird; D E Joshua; A Child; J Harris; H Kronenberg
Journal:  Aust N Z J Med       Date:  1989-04

10.  A second-generation vaccine protects against the psychoactive effects of cocaine.

Authors:  M R Carrera; J A Ashley; P Wirsching; G F Koob; K D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-06       Impact factor: 11.205

View more
  9 in total

Review 1.  The need for speed: an update on methamphetamine addiction.

Authors:  Alasdair M Barr; William J Panenka; G William MacEwan; Allen E Thornton; Donna J Lang; William G Honer; Tania Lecomte
Journal:  J Psychiatry Neurosci       Date:  2006-09       Impact factor: 6.186

2.  Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy.

Authors:  Katherine E Cornish; Andrew C Harris; Mark G LeSage; Dan E Keyler; Danielle Burroughs; Cathy Earley; Paul R Pentel
Journal:  Int Immunopharmacol       Date:  2011-07-28       Impact factor: 4.932

Review 3.  Vaccines against drug abuse.

Authors:  X Y Shen; F M Orson; T R Kosten
Journal:  Clin Pharmacol Ther       Date:  2011-11-30       Impact factor: 6.875

Review 4.  Pharmacological approaches to methamphetamine dependence: a focused review.

Authors:  Laurent Karila; Aviv Weinstein; Henri-Jean Aubin; Amine Benyamina; Michel Reynaud; Steven L Batki
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

5.  Dose-dependent changes in the locomotor responses to methamphetamine in BALB/c mice: low doses induce hypolocomotion.

Authors:  Rana A K Singh; Therese A Kosten; Berma M Kinsey; Xiaoyun Shen; Angel Y Lopez; Thomas R Kosten; Frank M Orson
Journal:  Pharmacol Biochem Behav       Date:  2012-08-28       Impact factor: 3.533

Review 6.  Development of active and passive human vaccines to treat methamphetamine addiction.

Authors:  W Brooks Gentry; Daniela Rüedi-Bettschen; S Michael Owens
Journal:  Hum Vaccin       Date:  2009-04-20

Review 7.  Management of methamphetamine abuse and dependence.

Authors:  Walter Ling; Richard Rawson; Steve Shoptaw; Walter Ling
Journal:  Curr Psychiatry Rep       Date:  2006-10       Impact factor: 8.081

8.  Cloning and characterization of a hybridoma secreting a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-specific monoclonal antibody and recombinant F(ab).

Authors:  Heather Wanczyk; Tolga Barker; Debra Rood; Daniel I Zapata; Amy R Howell; Stewart K Richardson; John Zinckgraf; Gregory P Marusov; Michael A Lynes; Lawrence K Silbart
Journal:  Toxins (Basel)       Date:  2013-03-19       Impact factor: 4.546

Review 9.  Preclinical Evaluation of Vaccines to Treat Opioid Use Disorders: How Close are We to a Clinically Viable Therapeutic?

Authors:  E Andrew Townsend; Matthew L Banks
Journal:  CNS Drugs       Date:  2020-05       Impact factor: 5.749

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.